CN1850100A - Medicinal composition for treating vagina disease - Google Patents
Medicinal composition for treating vagina disease Download PDFInfo
- Publication number
- CN1850100A CN1850100A CN 200610057867 CN200610057867A CN1850100A CN 1850100 A CN1850100 A CN 1850100A CN 200610057867 CN200610057867 CN 200610057867 CN 200610057867 A CN200610057867 A CN 200610057867A CN 1850100 A CN1850100 A CN 1850100A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- nifuratel
- nysfungin
- promestriene
- described pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 208000013464 vaginal disease Diseases 0.000 title description 4
- 239000000829 suppository Substances 0.000 claims abstract description 18
- 239000002552 dosage form Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- SRQKTCXJCCHINN-NYYWCZLTSA-N nifuratel Chemical compound O=C1OC(CSC)CN1\N=C\C1=CC=C([N+]([O-])=O)O1 SRQKTCXJCCHINN-NYYWCZLTSA-N 0.000 claims description 35
- 229960002136 nifuratel Drugs 0.000 claims description 35
- IUWKNLFTJBHTSD-AANPDWTMSA-N promestriene Chemical compound C1C[C@]2(C)[C@@H](OC)CC[C@H]2[C@@H]2CCC3=CC(OCCC)=CC=C3[C@H]21 IUWKNLFTJBHTSD-AANPDWTMSA-N 0.000 claims description 33
- 229960004765 promestriene Drugs 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 210000001215 vagina Anatomy 0.000 claims description 24
- 229920000858 Cyclodextrin Polymers 0.000 claims description 9
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 9
- -1 hydroxypropyl Chemical group 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 241001597008 Nomeidae Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 23
- 238000002360 preparation method Methods 0.000 abstract description 12
- 239000003937 drug carrier Substances 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract 1
- 229940049018 mycostatin Drugs 0.000 abstract 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 5
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 5
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 239000005662 Paraffin oil Substances 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 208000027709 Vulvovaginal disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicine composition for curing vaginopathy. Said medicine composition contains praestrene, nifurtair and mycostatin which can be used as active component and pharmaceutically-acceptable carrier. Said medicine composition can be made into the dosage forms, such as suppository, capsule, tablet, ointment and lotion suitable for intravaginal administration. Besides, said invention also provides its preparation method.
Description
Invention field
The present invention relates to a kind of pharmaceutical composition, be specifically related to be used for the treatment of the pharmaceutical composition of vagina, its with nifuratel, nysfungin and promestriene as active component.
Background technology
The gynaecologic vaginal disease is women's commonly encountered diseases and a frequently-occurring disease, and trichomonal vaginitis, bacterial vaginosis and vulvovaginal candidiasis are comparatively typical gynaecologic vaginal diseases, and its sickness rate rises year by year.Clinically can be of a great variety for the medicine that vagina is selected for use, but from therapeutic effect and drug resistance aspect, the relevant preparation of nifuratel is reasonable selection, the preparation of at present domestic relevant nifuratel is mainly the oral tablet of nifuratel, but the side effect of nifuratel oral tablet is bigger, untoward reaction is more, and effect is poor relatively, and bioavailability is low.
Have the compound preparation that contains nifuratel and nysfungin at present, as ordinary suppository, effervescent tablet and soft capsule etc.Nifuratel-nysfungin is by suppressing the pyruvate dehydrogenase system of pathogen, the blocking-up tricarboxylic acid cycle has inhibition or killing action to fungus, antibacterial and protozoon, can promote the growth and breeding of vagina lactobacillus, keep the microecology in vaginas balance, recurrence has important effect for prevention of inflammation.This compound preparation adopts the approach of vagina administration, though the side effect of having avoided oral administration to produce effectively, but still there is a untoward reaction, clinical mainly show as occur that slight pudendum is scorching hot, vaginal dryness and feeling sick, and have still that bioavailability of medicament is low, drug absorption is lower, drug action is of short duration, not steadily, need the characteristics of multiple dosing.
Promestriene promotes the differentiation and the maturation of vagina epithelium mucomembranous cell by the performance estrogen function, has effect synthetic and the secretion glycogen simultaneously, and can promote DoderleinShi bacillus (vagina bacillus acidophilus's) regeneration, and produce lactic acid, stimulate to change intravaginal sour environment.Promestriene is widely used clinically, is mainly emulsifiable paste, soft capsule, suppository, in order to the treatment vulvovaginal disease, as contracting property of flaccidity vaginitis, outer impotence contract, vaginal orifice atrophy etc., also can be used for seborrheic dermatitis.
Still nifuratel, nysfungin and promestriene are not united at present report or the corresponding techniques enlightenment of using the treatment vagina.
Summary of the invention
The inventor finds first: promestriene is except the effect of the anti-inflammatory of bringing into play self, the more important thing is that promestriene improves patient's self immunity, excite the repair function of patient's body self, and this function can reduce the untoward reaction of nifuratel-nysfungin, quicken patient's self rehabilitation simultaneously, show as the transference cure of untoward reaction, therapeutic effect improves, and shorten the course of treatment of rehabilitation.
The inventor is on the basis of nifuratel-nysfungin preparation, and the research through a large amount of adds promestriene in active constituents of medicine, eliminated above-mentioned untoward reaction effectively, makes the drug action of medicine lasting and steady.
Therefore, the purpose of this invention is to provide a kind of pharmaceutical composition that comprises promestriene, nifuratel and nysfungin, be used for the treatment of the gynaecologic vaginal disease, thereby select for doctor and patient provides a kind of better medication.
In one aspect, the invention provides a kind of pharmaceutical composition that is used for the treatment of vagina, it contains promestriene, nifuratel and nysfungin as active component, daily dose≤the 0.5g of 0.1g≤nifuratel wherein, preferably, 0.2g the daily dose≤0.4g of≤nifuratel, most preferably the daily dose of nifuratel is 0.3g; The daily dose of 50,000 IU≤nysfungin≤200,000 IU, preferably, the daily dose of 100,000 IU≤nysfungin≤200,000 IU, the daily dose of most preferred nysfungin are 150,000 IU; The daily dose of 5mg≤promestriene is≤10mg, and preferably the daily dose of 6mg≤promestriene is≤8mg, and most preferably the daily dose of promestriene is 8mg.
Pharmaceutical composition of the present invention is also chosen wantonly and is contained pharmaceutically acceptable carrier.
In a further preferred embodiment, pharmaceutical composition of the present invention also contains the clathrate material of main part.Described clathrate material of main part is cyclodextrin and/or its derivant, is selected from beta-schardinger dextrin-(β-CD), methyl beta-schardinger dextrin-(M-β-CD), hydroxypropyl (HP-β-CD), ethoxy beta-schardinger dextrin-(HE-β-CD), cyclodextrin polymer, ethyl beta-schardinger dextrin-(E-β-CD) and branching cyclodextrin.
Active component, promptly the mixture of promestriene, nifuratel and nysfungin and cyclodextrin and/or its derivant are mixed and made into clathrate according to 3: 1～1: 1, preferred 2: 1 weight ratio.
Pharmaceutical composition of the present invention can be prepared into the dosage form of intravaginal administration, including, but not limited to suppository, capsule, tablet, emulsifiable paste and washing liquid.
The vagina that pharmaceutical composition of the present invention is used for the treatment of is including, but not limited to bacterial vaginitis, trichomonal vaginitis, candidal vulvovaginitis and vagina mixed infection, vagina administration, once a day.
Specific embodiments
Below specify various aspects of the present invention and feature by preferred embodiment.It should be appreciated by those skilled in the art that these embodiment just are used for illustration purpose, and do not limit the scope of the invention.Protection scope of the present invention only is subjected to the restriction of claims.Under the condition that does not deviate from claims scope.Those skilled in the art can carry out various modifications and improvement to various aspects of the present invention, and these modifications and improvement also belong to protection scope of the present invention.For instance; though in the embodiment of the invention pharmaceutical composition of the present invention is made suppository; but those skilled in the art is after reading present specification; to be easy to prepare other forms of pharmaceutical compositions of the present invention such as capsule, tablet, emulsifiable paste, washing liquid, so these dosage forms are positioned within protection scope of the present invention according to description of the invention.
In addition, unless it should be noted that and specialize, below among the embodiment used various materials and reagent all be material and reagent commonly used in this area, can obtain by conventional commercial sources; Method therefor is and well known to a person skilled in the art conventional method.
Embodiment 1-prescription 1
Nifuratel with 30g, the nysfungin of 3g (tiring of 1mg is equivalent to 5000 nysfungin units), 0.8g the promestriene mix homogeneously, then mixture is mixed to mill as inclusion agents with the beta-schardinger dextrin-of 17.9g and make beta-CD inclusion, then clathrate and 163.5g are melted under 60-80 ℃ of water-bath and refrigerative a little semi-synthetic fatty acid ester is milled and mixed, when treating that temperature is reduced to 40 ℃, be poured in the bolt mould that scribbles paraffin oil, scrape off redundance after the cooling, take out molding suppository, packing is promptly made 100 of controlled-releasing vaginal suppositorys, makes every to contain nifuratel 0.3g, nysfungin 150,000 IU and promestriene 8mg.
Embodiment 2-prescription 2
Nifuratel with 50g, the nysfungin of 3g (tiring of 1mg is equivalent to 5000 nysfungin units), 0.8g the promestriene mix homogeneously, then mixture is mixed to mill as inclusion agents with the beta-schardinger dextrin-of 26.9g and make compound beta-CD inclusion, then clathrate and 246g are melted under 60-80 ℃ of water-bath and refrigerative a little semi-synthetic fatty acid ester is milled and mixed, when treating that temperature is reduced to 40 ℃, be poured in the bolt mould that scribbles paraffin oil, scrape off redundance after the cooling, take out molding suppository, packing is promptly made 100 of controlled-releasing vaginal suppositorys, makes every to contain nifuratel 0.5g, nysfungin 150,000 IU and promestriene 8mg.
Embodiment 3-prescription 3
Nifuratel with 30g, the nysfungin of 4g (tiring of 1mg is equivalent to 5000 nysfungin units), the promestriene mix homogeneously of 1g, then mixture is mixed to mill as inclusion agents with the beta-schardinger dextrin-of 17.5g and make compound beta-CD inclusion, then clathrate and 230g are melted under 60-80 ℃ of water-bath and refrigerative a little semi-synthetic fatty acid ester is milled and mixed, when treating that temperature is reduced to 40 ℃, be poured in the bolt mould that scribbles paraffin oil, scrape off redundance after the cooling, take out molding suppository, packing is promptly made 100 of controlled-releasing vaginal suppositorys, makes every to contain nifuratel 0.3g, nysfungin 200,000 IU and promestriene 10mg.
Embodiment 4-prescription 4
Nifuratel with 50g, the nysfungin of 4g (tiring of 1mg is equivalent to 5000 nysfungin units), the promestriene mix homogeneously of 1g, then mixture is mixed to mill as inclusion agents with the beta-schardinger dextrin-of 19g and make compound beta-CD inclusion, then clathrate and 222g are melted under 60-80 ℃ of water-bath and refrigerative a little semi-synthetic fatty acid ester is milled and mixed, when treating that temperature is reduced to 40 ℃, be poured in the bolt mould that scribbles paraffin oil, scrape off redundance after the cooling, take out molding suppository, packing is promptly made 100 of controlled-releasing vaginal suppositorys, makes every to contain nifuratel 0.5g, nysfungin 200,000 IU and promestriene 10mg.
Semi-synthetic fatty acid ester among the above embodiment all can replace with other excipient commonly used in semi-synthetic cocos nucifera oil fat or the pharmaceutical technology.The fat-soluble substrate of the general selection of excipient, its fusion temperature is preferably between 37-40 ℃.
Ultraviolet spectra is identified and the X-diffraction analysis is identified and all shown after medicinal mixture and beta-schardinger dextrin-are milled and formed clathrate; The differential scanning calorimetry has also confirmed the formation of clathrate: under the melting temperature of nifuratel, spike disappears in the clathrate, and this peak of physical mixed still exists.
Embodiment 5: local excitation and anxious poison research
Be subjected to the reagent thing: the preparation method by ordinary suppository is directly made common suppository, contains nifuratel 0.5g, nysfungin 200,000 IU and promestriene 8mg in making every;
The positive control medicine: the preparation method by ordinary suppository is directly made common suppository, only contains nifuratel 0.5g and nysfungin 200,000 IU in making every;
The negative control medicine: press the preparation method of ordinary suppository, preparation does not contain the substrate figuration suppository of medicine;
Adopting rabbit is local excitation and the anxious poison test that laboratory animal is carried out three kinds of suppositorys.
To being subjected to three dosage of examination group design, be respectively high dose group, dosage is equivalent to 20 times of human body consumption; Middle dosage group, dosage is equivalent to 10 times of human body consumption; Low dose group, dosage are equivalent to 3.8 times of human body consumption;
One group of positive controls, dosage are equivalent to 10 times of human body consumption.
Usage: used dosage is every day twice, but total dosage is no more than above-mentioned requirements, and medicine is filled in the animal intravaginal; Observed 7 days.Leading indicator: the activity of animal, feed, defecation, fur, the vagina outward appearance, it is no abnormal etc. to have or not edema, hyperemia, ulceration and secretions to have.
Sacrificed by exsanguination rabbit after the last administration.1. dissect pelvic cavity perusal reproductive system and the surrounding tissue organ has or not abnormal phenomenas such as edema, hyperemia, erosion; 2. dissect ANOMALOUS VARIATIONS such as vagina perusal vaginal walls color, edema, hyperemia, erosion, ulcer; 3. win part animal vagina and carry out pathological section, and observe, take a picture.
Experimental result:
1. general reaction: administration and viewing duration are subjected to examination group and positive controls, negative control group animal activity, feed, defecation, fur etc. all no abnormal, body weight, breathing, heart rate, Non Apparent Abnormality.
2. vagina is dissected perusal: be subjected to examination group, negative control group not to have abnormal phenomenas such as hyperemia, swelling and surrounding tissue adhesion, and positive controls has slight red and swollen phenomenon.
3. vagina pathology structure observation: select the animal subject vagina to do the pathology section at random, carry out histological examination, the result does not have pathology and changes.
Observe to find, contain promestriene be subjected to reagent thing group without any abnormal phenomena; And untoward reaction has appearred in the control drug group that does not contain promestriene; But two groups pathology are all no abnormal.Description of test, the adding of promestriene have the effect that alleviates nifuratel and nysfungin untoward reaction.
Embodiment 6: the long term toxicity research of the local application of compound preparation
Be subjected to the reagent thing: with embodiment 5
Method: according to the design of above-mentioned three dosage groups that are subjected to the examination group, adopt rat to experimentize, make high, medium and low dosage group be equivalent to 40,20,10 times of amounts of human body administration respectively, three dosage are administered once every day, observed 30 days repeated experiments three times continuously.
The result shows that animal whole body and vagina part there is no toxic reaction and local irritation; Pathological change is not seen in section film-making microscopic examination yet, shows that three dosage group medicines all do not have pathogenic effects to each layer of vagina, and long-term prescription is very safe.
Embodiment 7: clinical research
Carry out the clinical trial of 192 examples in Beijing San Jia hospital, wherein matched group is one group, one group of test group, every group of each 96 routine patient, every group is divided trichomonal vaginitis group, bacterial vaginitis group, vulvovaginal candidiasis group again, each 32 example of every group, and the patient satisfies the requirement of clinical research; Before test group each group therapy corresponding with matched group aspect symptom, sign and lab testing equal no difference of science of statistics, during the treatment and treatment back is all with symptom, sign and the lab testing index as judgement.Efficacy determination is as follows:
Cure: symptom complete obiteration, lab testing feminine gender.
Effectively: the symptom complete obiteration, but the lab testing positive or symptom are obviously alleviated the lab testing feminine gender.
Invalid: symptom does not have improvement, the lab testing positive.
Trial drug is according to the compound controlled release suppository of embodiment 1 preparation, comprises promestriene 8mg, nifuratel 300mg and nysfungin 150000IU as effective ingredient.With finger medicine is sent into the vagina deep by the experimenter before sleeping evening, take measures, prevent medicine liquid leakage, once a day, continuous six days is a course of treatment.
Control drug is nifuratel/nysfungin suppository, comprises nifuratel 500mg and nysfungin 200000IU as effective ingredient.With finger medicine is sent into the vagina deep by the experimenter before sleeping evening, take measures, prevent medicine liquid leakage, once a day, continuous six days is a course of treatment.
The clinical efficacy of test group and matched group, total effects are analyzed with Ridit and are compared.Carry out statistical analysis with SAS6.12 software.Trichomonal vaginitis research (test group 32 examples, matched group 32 examples) the results are shown in following table 1.
Table 1
| The example number | Recovery from illness | Effectively | Invalid | Total effective rate | |||||
| The example number | Cure rate | The example number | Effective percentage | The example number | Inefficiency | ||||
| Trichomonal vaginitis | Test group | 32 | 22 | 69.7％ | 10 | 31.3％ | 0 | 0％ | 100％ |
| Matched group | 32 | 13 | 40.6％ | 16 | 50％ | 3 | 9.4％ | 90.6％ | |
As can be seen from Table 1, totally 32 examples of test group recovery from illness+effectively, total effective rate 100%, totally 29 examples of matched group recovery from illness+effectively, total effective rate is that significant difference (p＜0.05) is arranged between 90.6%, two group;
Bacterial vaginitis research (test group 32 examples, matched group 32 examples) the results are shown in following table 2.
Table 2
| The example number | Recovery from illness | Effectively | Invalid | Total effective rate | |||||
| The example number | Cure rate | The example number | Effective percentage | The example number | Inefficiency | ||||
| Bacterial vaginitis | Test group | 32 | 19 | 60.4％ | 12 | 37.5％ | 1 | 3.1％ | 96.9％ |
| Matched group | 32 | 13 | 40.6％ | 18 | 56.3％ | 1 | 3.1％ | 96.9％ | |
As can be seen from Table 2, totally 31 examples of test group recovery from illness+effectively, total effective rate 96.9%, totally 31 examples of matched group recovery from illness+effectively, total effective rate is no difference of science of statistics between 96.6%, two group (p＞0.05); But on cure rate, difference is apparent in view, and test group is significantly better than matched group;
Vulvovaginal candidiasis research (test group 32 examples, matched group 32 examples) the results are shown in following table 3.
Table 3
| The example number | Recovery from illness | Effectively | Invalid | Total effective rate | |||||
| The example number | Cure rate | The example number | Effective percentage | The example number | Inefficiency | ||||
| Vulvovaginal candidiasis | Test group | 32 | 2l | 65.6％ | 10 | 31.3％ | 1 | 3.1 | 96.9％ |
| Matched group | 32 | 11 | 34.3％ | 18 | 56.3％ | 3 | 9.4 | 90.6％ | |
As can be seen from Table 3, totally 31 examples of test group recovery from illness+effectively, total effective rate 96.9%, totally 29 examples of matched group recovery from illness+effectively, total effective rate is that significant difference (p＜0.05) is arranged between 90.6%, two group; On cure rate, test group is significantly better than matched group, significant difference on the statistics.
Following table 4 is the comparison of test group and matched group untoward reaction.
Table 4
| Group | Pudendum is scorching hot | Vaginal dryness | Feel sick | Add up to |
| Test group (96) matched group (96) | 0 7 | 0 9 | 0 4 | 0 20 |
The stronger confirmation in untoward reaction of test group and matched group zooperal result, illustrate that promestriene obviously reduces the side effect that nifuratel produces.
Claims (13)
1. the pharmaceutical composition that is used for the treatment of vagina, it contains promestriene, nifuratel and nysfungin as active component, daily dose≤the 0.5g of 0.1g≤nifuratel wherein, the daily dose of 50,000 IU≤nysfungin≤200,000 IU, the daily dose≤10mg of 5mg≤promestriene.
2. the described pharmaceutical composition of claim 1, the wherein daily dose≤0.4g of 0.2g≤nifuratel.
3. the described pharmaceutical composition of claim 2, wherein the daily dose of nifuratel is 0.3g.
4. the described pharmaceutical composition of claim 1, the wherein daily dose of 100,000 IU≤nysfungin≤200,000 IU.
5. the described pharmaceutical composition of claim 4, wherein the daily dose of nysfungin is 150,000 IU.
6. the described pharmaceutical composition of claim 1, wherein the daily dose of 6mg≤promestriene is≤8mg.
7. the described pharmaceutical composition of claim 6, wherein the daily dose of promestriene is 8mg.
8. the described pharmaceutical composition of claim 1, it also contains the clathrate material of main part.
9. the described pharmaceutical composition of claim 8, wherein said clathrate material of main part is cyclodextrin and/or its derivant, is selected from beta-schardinger dextrin-, methyl beta-schardinger dextrin-, hydroxypropyl, ethoxy beta-schardinger dextrin-, cyclodextrin polymer, ethyl beta-schardinger dextrin-and branching cyclodextrin.
10. the described pharmaceutical composition of claim 9, wherein the weight ratio of the mixture of promestriene, nifuratel and nysfungin and cyclodextrin and/or its derivant is 3: 1～1: 1.
11. the described pharmaceutical composition of claim 10, wherein the weight ratio of the mixture of promestriene, nifuratel and nysfungin and cyclodextrin and/or its derivant is 2: 1.
12. each described pharmaceutical composition in the aforementioned claim, it is prepared into the dosage form of intravaginal administration.
13. the described pharmaceutical composition of claim 12, the dosage form of wherein said intravaginal administration are suppository, capsule, tablet, emulsifiable paste or washing liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100578676A CN100394919C (en) | 2006-03-01 | 2006-03-01 | Medicinal composition for treating vagina disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100578676A CN100394919C (en) | 2006-03-01 | 2006-03-01 | Medicinal composition for treating vagina disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1850100A true CN1850100A (en) | 2006-10-25 |
| CN100394919C CN100394919C (en) | 2008-06-18 |
Family
ID=37131612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100578676A Expired - Fee Related CN100394919C (en) | 2006-03-01 | 2006-03-01 | Medicinal composition for treating vagina disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100394919C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579473A (en) * | 2012-01-17 | 2012-07-18 | 程雪翔 | Nifuratel-nysfungin gel and preparation method thereof |
| CN102813938A (en) * | 2012-09-14 | 2012-12-12 | 扬州大学 | Llex A-cyclodextrin polymer medicine composition for preventing and curing atherosclerosis and preparation method thereof |
| CN104434942A (en) * | 2014-11-19 | 2015-03-25 | 江苏悦兴药业有限公司 | Nifuratel nysfungin vaginal soft capsule and preparation process thereof |
| CN112972418A (en) * | 2021-05-18 | 2021-06-18 | 北京金城泰尔制药有限公司 | Nifuratel nysfungin vaginal soft capsule and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2832311B1 (en) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | FILM-FORMING POWDER, COMPOSITIONS COMPRISING SAME, PREPARATION METHODS AND USES THEREOF |
| CA2523830A1 (en) * | 2003-04-30 | 2004-11-11 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
| ITMI20031640A1 (en) * | 2003-08-08 | 2005-02-09 | Mipharm S P A | BASE FOR BIOADHESIVE GEL. |
| CN1600315A (en) * | 2003-09-22 | 2005-03-30 | 陈云芳 | Soft capsule combination of Cloquinate/Promestriene in use for vagina |
-
2006
- 2006-03-01 CN CNB2006100578676A patent/CN100394919C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579473A (en) * | 2012-01-17 | 2012-07-18 | 程雪翔 | Nifuratel-nysfungin gel and preparation method thereof |
| CN102813938A (en) * | 2012-09-14 | 2012-12-12 | 扬州大学 | Llex A-cyclodextrin polymer medicine composition for preventing and curing atherosclerosis and preparation method thereof |
| CN104434942A (en) * | 2014-11-19 | 2015-03-25 | 江苏悦兴药业有限公司 | Nifuratel nysfungin vaginal soft capsule and preparation process thereof |
| CN112972418A (en) * | 2021-05-18 | 2021-06-18 | 北京金城泰尔制药有限公司 | Nifuratel nysfungin vaginal soft capsule and preparation method thereof |
| CN112972418B (en) * | 2021-05-18 | 2021-08-27 | 北京金城泰尔制药有限公司 | Nifuratel nysfungin vaginal soft capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100394919C (en) | 2008-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8586549B2 (en) | Composition and method for modulating and maintaining vaginal bacterial flora and vaginal acidity | |
| CN1251763A (en) | Process for preparing Chinese medicine 'Qianjin tablets' for treating gynopathy | |
| CN1840154A (en) | Ointment for treating nervous damage and preparation method thereof | |
| CN1308027C (en) | Medicinal formulation for treating skin tinea | |
| CN101036695B (en) | Oil-in-water type nanometer emulsion of elecampane oil and litsea citrata oil and the method for preparing the same | |
| CN100394919C (en) | Medicinal composition for treating vagina disease | |
| CN101874809A (en) | Local anti-inflammatory external medicinal composition using glycerol DMSO mixed solvent | |
| CN1899351A (en) | Medicine for treating hyperplasia of mammary glands and its preparing method | |
| EP1374903B1 (en) | Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases | |
| CN1927322A (en) | Liposoluble traditional medicine bougie for treating acute and chronic prostatitis, and manufacturing technique thereof | |
| CN103520262B (en) | A kind of lipid soluble gynecological gel | |
| CN101049329A (en) | Application of angelica oil in raising level of estradiol from internal source for treating estradiol related disease | |
| CN100408041C (en) | Medicine composition for treating valval and/or vaginal infection | |
| CN1895433A (en) | Chinese-medicinal composition for treating acne, its preparation and use | |
| CN1781510A (en) | Use of sea-buckthorn fruit oil and/or fruit slag oil in preparing medicine for treating osteoporosis | |
| CN103432486B (en) | Traditional Chinese medicine composition for treating leukoplakia vulvae | |
| CN1264508C (en) | Arteannuin preparation for treating gynecopathy | |
| CN1159048C (en) | Process for preparing patch 'Jingubitong' | |
| CN100340263C (en) | Suppository for treating bacterial vaginitis | |
| CN1219527C (en) | Ointment for curing acne and its preparation method | |
| CN1063632C (en) | External use liniment for curing dermatosis | |
| CN1939470A (en) | Chinese medicinal plaster with analgetic, hemostatic repercussive and sore-arresting functions | |
| CN101077360A (en) | Medicinal composition for treating sugar diabetes skin ulcer and preparation method thereof | |
| CN106983822A (en) | It is a kind of to treat Chinese medicine composition of vaginitis and its preparation method and application | |
| CN100522176C (en) | Medicine composition for treating vaginal diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: BEIJING LANEVA PHARMACEUTICAL CO.,LTD. Assignor: Yang Jun Contract fulfillment period: 2009.9.16 to 2014.9.15 Contract record no.: 2009990001226 Denomination of invention: Medicinal composition for treating vagina disease Granted publication date: 20080618 License type: Exclusive license Record date: 20091104 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.16 TO 2014.9.15; CHANGE OF CONTRACT Name of requester: BEIJING LANGYI PHARMACEUTICAL CO., LTD. Effective date: 20091104 |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING LANEVA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YANG JUN Effective date: 20150319 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100020 CHAOYANG, BEIJING TO: 100024 CHAOYANG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150319 Address after: 100024 No. 559 Shuangqiao Village, Guan Zhuang Town, Beijing, Chaoyang District Patentee after: BEIJING LANEVA PHARMACEUTICAL CO.,LTD. Address before: 100020, No. 903, building 1302, nine district, Chaoyang District, Beijing, Jinsong Patentee before: Yang Jun |
|
| CP03 | Change of name, title or address |
Address after: 101300 No.9 Mintai Road, Beiwu Town, Shunyi District, Beijing Patentee after: Beijing Jincheng Taier Pharmaceutical Co.,Ltd. Address before: 100024 No. 559, shuangqiaoli, Guanzhuang Township, Chaoyang District, Beijing Patentee before: BEIJING LANEVA PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080618 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |